{"id":485881,"date":"2026-01-02T00:11:16","date_gmt":"2026-01-02T00:11:16","guid":{"rendered":"https:\/\/www.europesays.com\/us\/485881\/"},"modified":"2026-01-02T00:11:16","modified_gmt":"2026-01-02T00:11:16","slug":"should-you-buy-pfizer-while-its-under-30","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/485881\/","title":{"rendered":"Should You Buy Pfizer While It&#8217;s Under $30?"},"content":{"rendered":"\n<ul class=\"yf-h8k6hx\">\n<li class=\"yf-h8k6hx\">\n<p class=\"yf-7hmkaz\">Pfizer has been struggling for several years.<\/p>\n<\/li>\n<li class=\"yf-h8k6hx\">\n<p class=\"yf-7hmkaz\">The company&#8217;s pipeline could help it turn things around.<\/p>\n<\/li>\n<li class=\"yf-h8k6hx\">\n<p class=\"yf-7hmkaz\">It also has a solid dividend program and is attractively valued.<\/p>\n<\/li>\n<li class=\"yf-h8k6hx\">\n<p class=\"yf-7hmkaz\"><a class=\"link \" href=\"https:\/\/api.fool.com\/infotron\/infotrack\/click?apikey=35527423-a535-4519-a07f-20014582e03e&amp;impression=4636cee4-826b-424a-be9e-86630168ec69&amp;url=https%3A%2F%2Fwww.fool.com%2Fmms%2Fmark%2Fe-sa-nonbbn-kp%3Faid%3D8867%26source%3Disaedikp0000053%26ftm_cam%3Dsa-bbn-evergreen%26ftm_veh%3Dkeypoints_pitch_feed_yahoo%26ftm_pit%3D17670\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:10 stocks we like better than Pfizer \u203a;elm:context_link;itc:0;sec:content-canvas\">10 stocks we like better than Pfizer \u203a<\/a><\/p>\n<\/li>\n<\/ul>\n<p class=\"yf-7hmkaz\">Trading at a bit under $25 apiece, <strong>Pfizer<\/strong>&#8216;s (NYSE: PFE) shares appear tentatively cheap. However, the pharmaceutical giant reached these levels because it has faced significant headwinds, resulting in a poor stock market performance over the past three years.<\/p>\n<p class=\"yf-7hmkaz\">Yet, what is the outlook for the struggling giant from here? Is Pfizer worth investing in at current levels?<\/p>\n<p>    <img fetchpriority=\"high\" decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/ywAAAAAAQABAAACAUwAOw==\" alt=\"Person looking up while holding  their chin.\" loading=\"eager\" height=\"506\" width=\"960\" class=\"yf-lglytj loader\"\/> Image source: Getty Images.         <\/p>\n<p class=\"yf-7hmkaz\">Pfizer&#8217;s revenue and earnings have been inconsistent over the past few years. To make matters worse, the drugmaker will encounter important <a href=\"https:\/\/www.fool.com\/terms\/p\/patent-cliff\/?utm_source=yahoo-host-full&amp;utm_medium=feed&amp;utm_campaign=article&amp;referring_guid=cf60c7c0-bc23-4f8e-9a84-25158a2f0a19\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:patent cliffs;elm:context_link;itc:0;sec:content-canvas\" class=\"link \">patent cliffs<\/a> within a few years, including that of Eliquis, an anticoagulant and one of its best-selling drugs. Even so, the company has been gradually earning new approvals, some of which should have a meaningful impact on its financial results as label expansions are secured.<\/p>\n<p class=\"yf-7hmkaz\">Further, Pfizer has doubled down on acquisitions, which has helped it improve its pipeline. The company now has a comprehensive list of candidates across multiple therapeutic areas, with a particular focus on <a href=\"https:\/\/www.fool.com\/investing\/stock-market\/market-sectors\/healthcare\/cancer-stocks\/?utm_source=yahoo-host-full&amp;utm_medium=feed&amp;utm_campaign=article&amp;referring_guid=cf60c7c0-bc23-4f8e-9a84-25158a2f0a19\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:cancer;elm:context_link;itc:0;sec:content-canvas\" class=\"link \">cancer<\/a>. It also boasts a promising candidate for weight loss. Pfizer should launch several new products that will bolster its lineup through the end of the decade.<\/p>\n<p class=\"yf-7hmkaz\">Purchasing shares of top companies when they are down is a great way to earn excellent returns over the long run. Pfizer is a top pick to consider, given that it has been making the right moves to overcome slow (or non-existent) revenue growth and patent cliffs. And there are even more reasons to consider the stock. Here are three.<\/p>\n<p class=\"yf-7hmkaz\">First, Pfizer penned a deal with the Trump administration that will allow it to avoid tariffs for three years. Second, the company is a solid dividend payer. It has increased its payouts by 51.3% over the past decade, and boasts a juicy forward yield of 6.9%.<\/p>\n<p class=\"yf-7hmkaz\">Lastly, Pfizer is trading at 8.5 times forward earnings, much lower than the 18.4 healthcare sector average. All these make for compelling reasons to buy the stock.<\/p>\n<p class=\"yf-7hmkaz\">Before you buy stock in Pfizer, consider this:<\/p>\n<p class=\"yf-7hmkaz\">The Motley Fool Stock Advisor analyst team just identified what they believe are the\u00a0<strong><a href=\"https:\/\/api.fool.com\/infotron\/infotrack\/click?apikey=35527423-a535-4519-a07f-20014582e03e&amp;impression=d82663c6-320e-473a-a08a-352144dc5d04&amp;url=https%3A%2F%2Fwww.fool.com%2Fmms%2Fmark%2Fe-sa-bbn-bn%3Faid%3D8867%26source%3Disaeditxt0001162%26ftm_cam%3Dsa-bbn-evergreen%26ftm_veh%3Darticle_pitch_feed_yahoo%26ftm_pit%3D18417&amp;utm_source=yahoo-host-full&amp;utm_medium=feed&amp;utm_campaign=article&amp;referring_guid=cf60c7c0-bc23-4f8e-9a84-25158a2f0a19\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:10 best stocks;elm:context_link;itc:0;sec:content-canvas\" class=\"link \">10 best stocks<\/a><\/strong> for investors to buy now\u2026 and Pfizer wasn\u2019t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.<\/p>\n<p class=\"yf-7hmkaz\">Consider when <strong>Netflix<\/strong> made this list on December 17, 2004&#8230; if you invested $1,000 at the time of our recommendation,\u00a0<strong>you\u2019d have $505,641<\/strong>!* Or when <strong>Nvidia<\/strong> made this list on April 15, 2005&#8230; if you invested $1,000 at the time of our recommendation, <strong>you\u2019d have $1,143,283<\/strong>!*<\/p>\n","protected":false},"excerpt":{"rendered":"Pfizer has been struggling for several years. The company&#8217;s pipeline could help it turn things around. It also&hellip;\n","protected":false},"author":3,"featured_media":485882,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[35],"tags":[210,1141,1142,30898,67,132,68],"class_list":{"0":"post-485881","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-health-care","8":"tag-health","9":"tag-health-care","10":"tag-healthcare","11":"tag-pfizer","12":"tag-united-states","13":"tag-unitedstates","14":"tag-us"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/115822610837720911","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/485881","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=485881"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/485881\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/485882"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=485881"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=485881"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=485881"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}